Press Release

AMSTERDAM, November 30 /PRNewswire/ -- Elsevier, the world's leading publisher of scientific, medicaland technical products and services, today announced a major re-launch ofEmbase, its comprehensive biomedical database which holds over 20 millionindexed records from more than 7,000 active, peer reviewed journals.

Embase has long played a key role in the advancement of newbiomedical and pharmaceutical insights. Now, new developments and updatesinclude:

  - Enabling all biomedical researchers to use Embase --extending its "usability" from information specialists to also includeall biomedical and pharmaceutical scientists, and clinical andregulatory professionals. - New retrieval tools that further drive discovery, includingquick and easy refining of search results and the display of indexeddrug-drug and drug-disease relations. - Improved comprehensiveness through the addition of indexedarticles-in-press and conference abstracts. - To signify the enhanced focus on biomedical answers, theproduct has a new, fresh look and feel to it.

Thomas Gutjahr, Head of the Knowledge Center at ActelionPharmaceuticals Ltd., comments: "I'm very impressed by all the newimprovements which I believe will greatly help with pin-pointing certainsearches, e.g. drug-drug interactions or drug-disease searches."

Embase supports researchers with key tasks such as tracking ofdrug adverse events, comparing drug therapies, and Evidence Based Medicineresearch. It provides researchers with deep insights and understanding fromthe world's life sciences information, enabling effective discoveries towardsmedical discovery and treatment.

ABOUT ELSEVIER

Elsevier is a world-leading publisher of scientific, technical andmedical information products and services. The company works in partnershipwith the global science and health communities to publish more than 2,000journals, including The Lancet (http://www.thelancet.com) and Cell(http://www.cell.com), and close to 20,000 book titles, including majorreference works from Mosby and Saunders. Elsevier's online solutions includeScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com),Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) andNursing Consult (http://www.nursingconsult.com), which enhance theproductivity of science and health professionals, and the SciVal suite(http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com),which help research and health care institutions deliver better outcomes morecost-effectively.

A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is partof Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leadingpublisher and information provider, which is jointly owned by Reed ElsevierPLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

  Media Contacts: Tom Reller Elsevier +1-215-239-3508 t.reller@elsevier.com Emma Potter Kaizo PR +44-20-3043-4191 Emma.potter@kaizo.net